NuVasive Announces Preliminary Unaudited Full Year 2012 Revenue

NuVasive Announces Preliminary Unaudited Full Year 2012 Revenue
Results 
SAN DIEGO, CA -- (Marketwire) -- 01/09/13 --  NuVasive, Inc. (NASDAQ:
NUVA), a medical device company focused on developing minimally
disruptive surgical products and procedures for the spine, announced
today preliminary unaudited revenue results for the full year ended
December 31, 2012. NuVasive anticipates full year 2012 revenue of
approximately $619 million. The unaudited results compare to
previously issued guidance of $601 million to $606 million in revenue
for the full year 2012.  
NuVasive expects 2013 revenue to approximate $655 million. The
Company anticipates revenue growth will ramp over the course of the
year as the contribution from new product launches and new geographic
expansion accelerates near year end. Revenue guidance contemplates
stable market conditions with some continuation of the dynamics that
surfaced late in 2012, offset in part by the Company's ongoing
efforts to reestablish and sustain sales momentum.  
Alex Lukianov, Chairman and Chief Executive Officer, said, "Based on
our preliminary results, we achieved year over year revenue growth of
15% in 2012, ahead of our initial expectations at the start of the
year, and well above our most recent fourth quarter guidance
following a soft third quarter. NuVasive executed exceptionally well
to aggressively address market and competitive challenges in 2012. We
anticipate that our market share taking strategy and momentum can be
sustained in 2013. The entire NuVasive family remains laser focused
on changing spine surgery with innovative solutions and executing our
market share taking strategy to fuel growth at several multiples of
the industry while improving operating profitability." 
The Company announced anticipated full year 2012 revenue in advance
of the J.P. Morgan Healthcare Conference, where Chairman and Chief
Executive Officer, Alex Lukianov, will present at 9:00 a.m. PST
today, January 9, 2013. A live webcast of the presentation will be
available online from the investor relations page of the Company's
corporate website at www.nuvasive.com. After the live webcast, the
presentation will remain available on the website for 30 days.  
The Company is working to close the 2012 financial statements
 and to
finalize ongoing accounting adjustments, including those with
non-cash impacts. These non-cash items are expected to include an
impairment charge related to certain acquired assets resulting from
ongoing asset impairment testing. The Company will announce complete
financial and operating results of its fourth quarter and the full
year ended December 31, 2012, and will provide detailed revenue and
profitability guidance for the full year 2013 after the market closes
on February 26, 2013. The Company will hold a conference call to
discuss the results that day at 5:30 p.m. ET (2:30 p.m. PST). The
dial-in numbers are 1-877-407-9039 for domestic callers and
1-201-689-8470 for international callers. A live webcast of the
conference call will be available online from the investor relations
page of the Company's corporate website at www.nuvasive.com.  
After the live webcast, the call will remain available on NuVasive's
website, www.nuvasive.com, through March 26, 2013. In addition, a
telephone replay of the call will be available until March 12, 2013.
The replay dial-in numbers are 1-877-870-5176 for domestic callers
and 1-858-384-5517 for international callers. Please use pin number
406960.  
About NuVasive 
NuVasive is a medical device company focused on developing minimally
disruptive surgical products and procedurally integrated solutions
for the spine. The Company is the 4th largest player in the $7.9
billion global spine market. 
NuVasive's principal product offering is based on its Maximum Access
Surgery, or MAS(R) platform. The MAS platform combines several
categories of solutions that collectively minimize soft tissue
disruption during spine surgery with maximum visualization and safe,
easy reproducibility for the surgeon: a proprietary software-driven
nerve avoidance system and intra-operative monitoring support;
MaXcess(R), a unique split-blade retractor system; a wide variety of
specialized implants; and several biologic fusion enhancers. MAS
significantly reduces surgery time and returns patients to activities
of daily living much faster than conventional approaches. Having
redefined spine surgery with the MAS platform's lateral approach,
known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has
built an entire spine franchise. With over 75 products today spanning
lumbar, thoracic and cervical applications, the Company will continue
to expand and evolve its offering predicated on its R&D focus and
dedication to outstanding service levels supported by a culture of
Absolute Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to: the
risk that NuVasive's revenue or earnings projections may turn out to
be inaccurate because of the preliminary nature of the forecasts; the
risk of further adjustment, or unanticipated difficulty in selling
products or generating expected profitability; and other risks and
uncertainties more fully described in NuVasive's press releases and
periodic filings with the Securities and Exchange Commission.
NuVasive's public filings with the Securities and Exchange Commission
are available at www.sec.gov. NuVasive assumes no obligation to
update any forward-looking statement to reflect events or
circumstances arising after the date on which it was made. 
Contact: 
Michael J. Lambert 
EVP & Chief Financial Officer 
NuVasive, Inc. 
858-909-3394
investorrelations@nuvasive.com  
Investors:
Stephan Ogilvie 
VP, Corporate Development & Investor Relations
NuVasive, Inc.
201-322-6515
investorrelations@nuvasive.com 
Media:
Nicholas S. Laudico
The Ruth Group
646-536-7030
nlaudico@theruthgroup.com